| Literature DB >> 32923314 |
Xiaoxuan Zhang1,2, Helin Xing3, Feng Qi4, Hongchen Liu5, Lizeng Gao6, Xing Wang1,2,5.
Abstract
Bone defects caused by trauma, tumor resection, congenital malformation and infection are still a major challenge for clinicians. Biomimetic bone materials have attracted more and more attention in science and industry. Insulin and insulin-like growth factor-1 (IGF-1) have been increasingly recognized as an inducible factor for osteogenesis and angiogenesis. Spatiotemporal release of insulin may serve as the promising strategy. Considering the successful application of nanoparticles in drug loading, various insulin delivery systems have been developed, including (poly (lactic-co-glycolic acid), PLGA), hydroxyapatite (HA), gelatin, chitosan, alginate, and (γ-glutamic acid)/β-tricalcium phosphate, γ-PGA/β-TCP). Here, we have reviewed the progress on nanoparticles carrying insulin/IGF for bone regeneration. In addition, the key regulatory mechanism of insulin in bone regeneration is also summarized. The future application strategies and the challenges in bone regeneration are also discussed. © The author(s).Entities:
Keywords: Angiogenesis; Bone regeneration; Insulin; Insulin-like growth factor; Nanoparticles; Osteogenesis
Mesh:
Substances:
Year: 2020 PMID: 32923314 PMCID: PMC7484631 DOI: 10.7150/ntno.46408
Source DB: PubMed Journal: Nanotheranostics ISSN: 2206-7418
Characteristics of insulin/IGF-1 nanoparticles
| Carrier | Synthesis Method | Components | Drug | LE/EE | Size | Release behaviour | Effect in bone regeneration | Ref |
|---|---|---|---|---|---|---|---|---|
| PLGA | W/O/W system | DCM + PVA + PLGA | IGF-1 | EE = 78.3% | Initial burst release (55.3%, 48 h); | Promote osseointegration of dental implants. | ||
| PLGA | (W/O/W) system with SPG premix membrane | DCM + PVA + PLGA | Insulin | LE = 5.4% | 121.2 nm | Initial burst release (51%, 24 h) followed drug release over 5 days. | Bone mineral density (8 week): 0.96 ± 0.06 g/cm3. | |
| LE = 28.27% | 1.61 μm | Initial burst release (29%, 24 h); | Bone mineral density (8 week): 1.10 ± 0.07 g/cm3. | |||||
| LE = 33.72% | 21.45 μm | Initial lower burst (18%, 24 h); within a long period up to 2 weeks, the release rate was slow, but then increased in the second month. | Bone mineral density (8 week): 0.86 ± 0.07 g/cm3. | |||||
| HA | Dropwise aqueous | Ca(NO3)2/Sr(NO3)2/Zn(NO3)2 | Insulin | < 210 μm | SrHA/insulin promoted stem cell proliferation. | |||
| PLGA | Copolymerization method | HA + PEG-DM + DCC + DMAP | IGF-1 | LE = 99% | 131.3 nm | Initial burst release (4g within 24 h); | Increase proliferation of ADSCs on Ti substrates. | |
| PLGA | O/W emulsion | HA + DCM + PLGA + PVA + DA | IGF-1 | 223.71 μm | Increase proliferation, adhesion, and osteogenic differentiation of ADSCs. | |||
| Gelatin | W/W emulsion | PEG + Dex-GMA/gelatin | IGF-1 | LE = 5% | 30 μm | Initial burst release: 20.4 ± 1%, 24 h release: > 28 days. | Enhance periodontal tissue regeneration. | |
| Gelatin | Swell + crosslink | OPF + Gelatin microparticles | IGF-1 | 50-100 μm | Initial burst release (30%, 24 h); | Improves the subchondral bone morphology and the interaction with the surrounding chondral tissue. | ||
| Gelatin | Heating crosslink | OPF + Gelatin + Glutaraldehyde | IGF-1 | Loading 100-200 ng: EE = 100% | 50-100 μm | Initial burst release: (22%, 24 h); | ||
| Chitosan | Emulsification method | Chitosan + Cottonseed oil + TPP | IGF-1 | 70.02 ng | 50-80 μm | 3.31% (14 d) | ||
| Coacervation method | Acetic acid + Chitosan + TPP | IGF-1 | 168.7 ng | 500-700 μm | 30.68% (14 d) | Enhance pre-osteoblasts proliferation/differentiation. | ||
| Chitosan | W/O emulsion | Gelatin + Glyoxal + Chitosan | IGF-1 | Initial burst release: 48%, 24 h; | Increase ALP activity of W-20-17 cells. | |||
| Alginate | Electrospraying method | Sodium alginate chitosan flakes | IGF-1 | EE = 40% | 296 ± 18 μm | 60% within 24 h | Promote the proliferation and differentiation of cementoblasts. | |
| Two-step desolvation | γ-PGA + β-TCP | IGF-1 | 52.86% (12 d) | Sequential release of BMP-2 and IGF-1 significantly promoted the proliferation and differentiation of MC3T3-E1 cells. |
ADSCs: adipose-derived mesenchymal stem cells; ALP: alkaline phosphatase; BMP-2: bone morphogenetic protein 2; DA: dopamine; DCM: dichloromethane; DCC: 1,3-dicyclohexylcarbodiimide; Dex-GMA: dextran-glycidyl methacrylate; DMAP: 4-dimethylaminopyridine; HA: hydroxyapatite; IGF-1: insulin-like growth factor 1; LE/EE: loading efficiency/encapsulation efficiency; OPF: oligo(poly(ethylene glycol) fumarate); pDA: polydopamine; PEG: polyethylene glycol; PEG-DM: Poly(ethylene glycol) dimethyl ether; PLGA: poly (lactic-co-glycolic acid); PVA: polyvinyl alcohol; γ-PGA/β-TCP: (γ-glutamic acid)/β-tricalcium phosphate; SPG: Shirasu porous glass; SrHA: strontium substitution in HA; TPP: tripolyphosphate; W/O/W: water/oil/water.
Insulin/IGF-1 composited scaffolds in bone regeneration
| Nanoparticles | Scaffold | Drug | Characterizations of scaffold | Release behaviour of scaffold | Effect in bone regeneration | Ref |
|---|---|---|---|---|---|---|
| PLGA | nHAC/PLGA | Insulin | Nano-nHAC pore size: 127.4 ± 21.1 | Initial burst release (37% within 24 h); | Enhance proliferation and osteogenesis of BMSCs | |
| Insulin | Micron-nHAC pore size: 122.2 ± 11.4 μm | Initial burst release (23% within 24 h); | ||||
| Insulin | 10×Micron-nHAC pore size: 97.2 ± 20.9 μm | Initial burst release (16% within 24 h); | ||||
| Gelatin | Dex-GMA/Gelatin | IGF-1 | Loading 5 ng IGF-1 per mg of freeze-dried scaffold | Sustained release during 28 days. | Promoting the proliferation, metabolism and ALP activity of periodic metabolism fibroblasts. | |
| Gelatin | OPF | IGF-1 | Degradation: remained stable over 28 days in PBS; started to increase after 7 days in collagenase-PBS | Initial released (36.6 ± 8.8%, 4 days) | Enhance cartilage morphology in an osteochondral defect. | |
| Chitosan | Chitosan | Insulin | Scaffolds with 3-mm-height and 5-mm-diameter cylindrical shape | 5% insulin initial released: (40%, the first 4 days); | Enhance cartilage morphology and the cartilaginous genes Sox-9. | |
| Alginate/ | Chitosan | IGF-1 | Pore size:30-150 μm | Increased ECM synthesis, cell differentiation and mineralize nodule formation. |
ALP: alkaline phosphatase; BMSCs: bone marrow derived mesenchymal stromal cells; Dex-GMA: dextran-glycidyl methacrylate; ECM: extracellular matrix; IGF-1: insulin-like growth factor 1; nHAC: nano-hydroxyapatite/collagen; OPF: oligo(poly(ethylene glycol) fumarate); PBS: phosphate buffered saline; PLGA: poly (lactic-co-glycolic acid).